Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 51Fallopian Tube Neoplasms 28Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 15Pancreatic Neoplasms 13Breast Neoplasms, Male 11Lung Neoplasms 10Brenner Tumor 10Inflammatory Breast Neoplasms 7Uterine Cervical Neoplasms 5Endometrial Adenocarcinoma 5Adenocarcinoma of Lung 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Cholangiocarcinoma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Pleural Effusion, Malignant 3Pancreatic Adenocarcinoma 3Neoplasms 3Thymoma 2Neurotoxicity Syndromes 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinosarcoma 2Breast Carcinoma In Situ 2

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Carcinoma × Taxes × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡